SPShakti Prasad Pattanayak

Shakti Prasad Pattanayak

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Shakti Prasad Pattanayak has a total of 88 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Supplemental Figure 4 from Increased Glucose Availability Sensitizes Pancreatic Cancer to Macrophage-Targeting Immunotherapies

    by Jonathan J. Hue, Mehrdad Zarei, Priyashree Sunita, Sami O. Abul-Khoudoud, Goutam Dey, Hallie J. Graor, Katie E. Blise, Dove Keith, Shamilene Sivagnanam, Shakti P. Pattanayak, et al.

    Supplemental Figure 4 - Macrophage-targeting immunotherapies are associated with a protective effect for M1-like macrophage polarization in vitro without impacting macrophage viability. A.) Western blot of M0, M1-, and M2-like macrophages treated with vehicle or PLX3397 (100 nm) in high (25 mM) or low (1 mM) glucose conditions for 48 hours. B.) Baseline western blot of CSF1R and CCR2 in M0, M1-, and M2-like macrophages. C.) Western blot of CSF1R of M1- and M2-like macrophages in high and low glucose conditions. D.) Western blot of M1- and M2-like macrophages treated with vehicle or PF-4136309 (100 nm) in high (25 mM) or low (1 mM) glucose conditions for 48 hours. Protein quantification is normalized to α-Tubulin unless otherwise shown. E.) Bone marrow-derived macrophage survival (M1- and M2-like) treated with varying concentrations of PLX3397 (left) or PF-4136309 (right) in high (25 mM) or low (1 mM) glucose conditions after 4 days assessed via double-stranded DNA quantification (PicoGreen). F.) KPC cell survival treated with varying concentrations of PLX3397 in high (25 mM) or low (2.5 mM) glucose after 4 days assessed via double-stranded DNA quantification (PicoGreen).

  • Open Access

    Supplemental Figure 7 from Increased Glucose Availability Sensitizes Pancreatic Cancer to Macrophage-Targeting Immunotherapies

    by Jonathan J. Hue, Mehrdad Zarei, Priyashree Sunita, Sami O. Abul-Khoudoud, Goutam Dey, Hallie J. Graor, Katie E. Blise, Dove Keith, Shamilene Sivagnanam, Shakti P. Pattanayak, et al.

    Supplemental Figure 7 - Flow cytometric analysis of T cell infiltration following single and combination treatments in pancreatic tumors. Representative flow cytometry plots and quantitative analyses showing the effects of vehicle control, D30, PLX3397, PLX3397 + D30, PF-4136309, and PF-4136309 + D30 on intratumoral T cell populations. Tumor-derived single-cell suspensions were first gated on viable cells based on forward- and side-scatter properties, followed by identification of CD3+ T cells. CD3+ cells were subsequently subdivided into CD4+ and CD8+ T cell subsets as indicated. Representative contour plots illustrate the gating strategy and frequencies of each population, with arrows denoting the sequential gating steps. Bar graphs summarize the percentage of CD3+, CD4+, and CD8+ T cells across treatment groups. Data are presented as mean ± S.D. from independent biological replicates. Statistical significance was determined using one-way ANOVA with multiple-comparison correction. ns, not significant; * indicated p<0.05; ** indicated p<0.01; *** indicated p<0.001; **** indicates p<0.0001. All gates were defined using FMO controls and applied consistently across all samples.

  • Open Access

    Figure 5 from Increased Glucose Availability Sensitizes Pancreatic Cancer to Macrophage-Targeting Immunotherapies

    by Jonathan J. Hue, Mehrdad Zarei, Priyashree Sunita, Sami O. Abul-Khoudoud, Goutam Dey, Hallie J. Graor, Katie E. Blise, Dove Keith, Shamilene Sivagnanam, Shakti P. Pattanayak, et al.

    Representative IHC sections of pancreatic tumors from mice treated with vehicle control, D30, PLX3397, PLX3397 + D30, PF-4136309, or PF-4136309 + D30. A, Panels depict IHC staining for Ki-67 and cleaved caspase-3 across treatment groups. Brown chromogenic signal indicate positive staining with hematoxylin counterstaining of nuclei. Quantitative analysis of Ki-67 (B) and cleaved caspase-3 (C). D, Panels depict IHC staining for iNOS and CD163 across treatment groups. Magnified views are shows to better demonstrate differences. Pink chromogenic signal indicates positive staining with hematoxylin counterstaining of nuclei. Across treatment groups, qualitative differences in proliferative index, apoptotic activity, and macrophage polarization are evident. Scale bars, 100 μm. All images are representative of multiple tumors examined per group and were acquired using identical staining and imaging conditions. *, P < 0.05; **, P < 0.01; ****, P < 0.0001.

  • Open Access

    Supplemental Figure 5 from Increased Glucose Availability Sensitizes Pancreatic Cancer to Macrophage-Targeting Immunotherapies

    by Jonathan J. Hue, Mehrdad Zarei, Priyashree Sunita, Sami O. Abul-Khoudoud, Goutam Dey, Hallie J. Graor, Katie E. Blise, Dove Keith, Shamilene Sivagnanam, Shakti P. Pattanayak, et al.

    Supplemental Figure 5 - Principal component analysis (A.) and volcano plots (B.) from bulk RNA-sequencing of orthotopic pancreatic tumors. C57Bl/6J mice bearing KPC orthotopic tumors were randomized to normoglycemic or hyperglycemic conditions. Mice in the hyperglycemia group received D30 drinking water for 8 days prior to initiation of PLX3397 or vehicle treatment, whereas normoglycemic mice received standard drinking water. Tumors were harvested following treatment and subjected to bulk RNA-sequencing. Pairwise comparisons shown include vehicle vs D30, vehicle vs PLX3397, D30 vs combination, and PLX3397 vs combination. Abbreviations: Veh, vehicle; PLX, PLX3397; Combo, D30 plus PLX3397.

  • Open Access

    Supplemental Figure 11 from Increased Glucose Availability Sensitizes Pancreatic Cancer to Macrophage-Targeting Immunotherapies

    by Jonathan J. Hue, Mehrdad Zarei, Priyashree Sunita, Sami O. Abul-Khoudoud, Goutam Dey, Hallie J. Graor, Katie E. Blise, Dove Keith, Shamilene Sivagnanam, Shakti P. Pattanayak, et al.

    Supplemental Figure 11 - Durable response to immunotherapy in a patient with diabetes who developed metastatic disease after a pancreatectomy and progressed on chemotherapy. CA 19-9 (U/mL) values are depicted by the red line. Peripheral glucose levels (mg/dL) are depicted by the black line. The patient’s median glucose level over the course of treatment is depicted with the horizontal gray dashed line (190 mg/dL).Supplemental Figure 11 - Durable response to immunotherapy in a patient with diabetes who developed metastatic disease after a pancreatectomy and progressed on chemotherapy. CA 19-9 (U/mL) values are depicted by the red line. Peripheral glucose levels (mg/dL) are depicted by the black line. The patient’s median glucose level over the course of treatment is depicted with the horizontal gray dashed line (190 mg/dL).

  • Open Access

    Figure 3 from Increased Glucose Availability Sensitizes Pancreatic Cancer to Macrophage-Targeting Immunotherapies

    by Jonathan J. Hue, Mehrdad Zarei, Priyashree Sunita, Sami O. Abul-Khoudoud, Goutam Dey, Hallie J. Graor, Katie E. Blise, Dove Keith, Shamilene Sivagnanam, Shakti P. Pattanayak, et al.

    Hyperglycemia affects the immune profile of mice receiving macrophage-modulating immunotherapies. GO analysis of tumors from mice receiving standard water or D30 water with or without PLX3397 (A–D). Representative flow cytometry plots and quantitative analyses showing the effects of vehicle control, D30, PLX3397, PLX3397 + D30, PF-4136309, and PF-4136309 + D30 on tumor-associated macrophages and their functional subsets. Tumor-derived single-cell suspensions were gated sequentially on viable cells based on FSC-A and SSC-A properties, followed by the identification of F4/80+ macrophages (E). Representative contour plots illustrate the frequency of total F4/80+ macrophages across treatment groups. Macrophage polarization was further assessed by delineating M1-like macrophages (iNOS+; F) and M2-like macrophages (arginase-1+; G). PD-L1 expression on macrophages (H) was analyzed within the F4/80+ compartment. Bar graphs summarize the percentage of total macrophages, M1-like, M2-like, and PD-L1+ macrophage populations for each treatment group. Data are presented as the mean ± SD from independent biological replicates. Statistical significance was assessed using one-way ANOVA with multiple-comparison correction. ns, not significant; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. All gates were defined using fluorescence-minus-one (FMO) controls and applied uniformly across all samples.

  • Open Access

    Figure 1 from Increased Glucose Availability Sensitizes Pancreatic Cancer to Macrophage-Targeting Immunotherapies

    by Jonathan J. Hue, Mehrdad Zarei, Priyashree Sunita, Sami O. Abul-Khoudoud, Goutam Dey, Hallie J. Graor, Katie E. Blise, Dove Keith, Shamilene Sivagnanam, Shakti P. Pattanayak, et al.

    High glucose is needed to maintain the metabolic profile of M1-like macrophages in vitro. OCR (A) and ECAR (B) of M1- and M2-like macrophages at differing glucose levels after 48 hours of treatment, assessed via Seahorse extracellular flux analysis. C, OCR of M0 macrophages in high- and low-glucose conditions. D, PCA of metabolites from M1- and M2-like macrophages grown in high and low glucose. E, LC/MS quantification of glycolytic and tricarboxylic acid cycle metabolites in M1- and M2-like macrophages at indicated glucose concentrations after 48 hours of treatment (top). Corresponding Western blot of iNOS and arginase levels at the time of metabolite harvest are also depicted (bottom), with gel lanes represented in line with the heatmap experimental groups above. ***, P < 0.001; ns, not significant.

  • Open Access

    Supplemental Figure 10 from Increased Glucose Availability Sensitizes Pancreatic Cancer to Macrophage-Targeting Immunotherapies

    by Jonathan J. Hue, Mehrdad Zarei, Priyashree Sunita, Sami O. Abul-Khoudoud, Goutam Dey, Hallie J. Graor, Katie E. Blise, Dove Keith, Shamilene Sivagnanam, Shakti P. Pattanayak, et al.

    Supplemental Figure 10 - Effects of hyperglycemia and PLX3397 in an orthotopic model of hepatic metastases. A.) Median survival of C57Bl/6J mice with orthotopic hepatic metastases treated with PLX3397 with or without D30 water. Treatment was stopped after 60 days. An asterisk (*) indicates two mice in the combination group were euthanized after surviving 120 days. Photograph insert depicts gross appearance of multifocal hepatic metastases after splenic injection. B.) Peripheral glucose levels of mice bearing orthotopic hepatic metastases after 2 weeks of treatment. C.) Body weights throughout the study period. D.) Bioluminescence imaging of mice (n=3) treated with PLX3397 and D30 water alive at day 90. E.) Gross depiction of mice (n=2) after euthanasia (day 120) did not demonstrate evidence of hepatic metastases (left and middle). Gross depiction of mouse euthanized on day 95 due to signs of severe systemic illness demonstrates a large tumor in the right lobe of the liver, consistent with bioluminescence imaging (right). F.) Mice receiving PLX3397 combined with D30 develop progressive fur depigmentation.

  • Open Access

    Data from Increased Glucose Availability Sensitizes Pancreatic Cancer to Macrophage-Targeting Immunotherapies

    by Jonathan J. Hue, Mehrdad Zarei, Priyashree Sunita, Sami O. Abul-Khoudoud, Goutam Dey, Hallie J. Graor, Katie E. Blise, Dove Keith, Shamilene Sivagnanam, Shakti P. Pattanayak, et al.

    Pancreatic ductal adenocarcinoma (PDAC) is characterized by an immunosuppressive tumor microenvironment (TME) that limits the efficacy of immunotherapies. Many tumor-suppressive immune cells, including inflammatory macrophage subsets, rely on glycolysis to sustain effector function; however, the pancreatic TME is relatively glucose-limited. In this study, we investigated whether increasing glucose availability in the periphery, which in turn translates to increased intratumoral glucose, could enhance immune-based therapies in PDAC. In vitro, glucose restriction induced metabolic reprogramming of inflammatory (M1-like) macrophages toward an oxidative, M2-like state with reduced inflammatory effector markers. In immunocompetent mice, administration of 30% dextrose drinking water increased both peripheral and intratumoral glucose levels and modestly shifted tumor transcriptional profiles toward a more inflammatory state without altering overall immune cell abundance. When macrophage-targeting immunotherapies (colony stimulating factor 1 receptor inhibition with PLX3397 or C–C chemokine receptor type 2 inhibition with PF-4136309) were combined with systemic hyperglycemia, tumors exhibited a pronounced increase in iNOS+ M1-like macrophages, a reduction in arginase+ M2-like macrophages, enhanced CD8+ T-cell infiltration, and decreased abundance of tumor-associated fibroblasts. These immunotherapies improved overall survival in immunocompetent mice bearing orthotopic pancreatic tumors only when combined with hyperglycemia. Analyses of patient samples confirmed the presence of a favorable antitumor immune infiltrate with elevated glucose levels. Together, these findings identify glucose availability as a key regulator of macrophage polarization and immunotherapy efficacy in PDAC.Significance:PDAC is largely resistant to immunotherapies. Our findings identify glucose availability in the TME as a modifiable determinant of macrophage polarization and immunotherapy response. In preclinical models, transient hyperglycemia was associated with enhanced efficacy of macrophage-targeting immunotherapies and promoted a more inflammatory TME.

  • Open Access

    Figure 4 from Increased Glucose Availability Sensitizes Pancreatic Cancer to Macrophage-Targeting Immunotherapies

    by Jonathan J. Hue, Mehrdad Zarei, Priyashree Sunita, Sami O. Abul-Khoudoud, Goutam Dey, Hallie J. Graor, Katie E. Blise, Dove Keith, Shamilene Sivagnanam, Shakti P. Pattanayak, et al.

    Hyperglycemia improves efficacy of macrophage-targeting immunotherapies in vivo. A, Overall survival of C57Bl/6J mice with KPC orthotopic tumors treated with vehicle or PLX3397, with or without D30 water. B, Overall survival of mice with varying degrees of immunodeficiency (NSG, athymic nude, and C57Bl/6J) treated with PLX3397 with or without D30. C, Overall survival of C57Bl/6J mice with KPC orthotopic tumors treated with vehicle or PF-4136309, with or without D30. An asterisk (*) seen in A and C signifies that mice were alive at the end of the experiment. Median survival was plotted using the Kaplan–Meier method and compared using the log-rank test in the preceding survival experiments.